The effect of etanercept on Graves' ophthalmopathy: a pilot study


PurposeTo assess the effect of etanercept, an antitumour necrosis factor (anti-TNF) drug, on clinical signs in Graves' ophthalmopathy (GO).MethodsA total of 10 consecutive patients (seven female, three male) with recent-onset, active, mildly-to-moderately severe GO were treated with subcutaneous injections of 25 mg etanercept (Enbrel®) twice weekly during… (More)
DOI: 10.1038/sj.eye.6701768


2 Figures and Tables